Arovella Therapeutics Ltd (ALA) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-1.28x
Arovella Therapeutics Ltd (ALA) has a Cash Flow-to-Debt Ratio of -1.28x as of December 2025, meaning its operating cash flow of AU$-1.71 Million could theoretically repay -1% of its total liabilities (AU$1.33 Million) in one year. See financial agility of Arovella Therapeutics Ltd to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.28x
Operating CF / Total Liabilities
Operating Cash Flow
AU$-1.71 Million
AUD
Total Liabilities
AU$1.33 Million
AUD
Data as of
Dec 2025
Most recent filing
Arovella Therapeutics Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Arovella Therapeutics Ltd across 13 annual periods. For the full cash flow conversion analysis, see ALA cash flow metrics.
Annual Cash Flow-to-Debt Ratio for Arovella Therapeutics Ltd (2013–2025)
Year-by-year debt coverage analysis for Arovella Therapeutics Ltd.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.55x | AU$-6.93 Million | AU$1.52 Million | ▼ -35.2% |
| 2024 | -3.36x | AU$-6.91 Million | AU$2.06 Million | ▲ +11.2% |
| 2023 | -3.78x | AU$-6.40 Million | AU$1.69 Million | ▲ +3.7% |
| 2022 | -3.93x | AU$-6.27 Million | AU$1.60 Million | ▼ -89.1% |
| 2021 | -2.08x | AU$-3.54 Million | AU$1.71 Million | ▼ -85.4% |
| 2020 | -1.12x | AU$-2.88 Million | AU$2.57 Million | ▼ -2.2% |
| 2019 | -1.10x | AU$-2.50 Million | AU$2.28 Million | ▼ -122.8% |
| 2018 | -0.49x | AU$-2.55 Million | AU$5.18 Million | ▼ -82.2% |
| 2017 | -0.27x | AU$-854.22K | AU$3.16 Million | ▲ +56.4% |
| 2016 | -0.62x | AU$-1.80 Million | AU$2.91 Million | ▲ +30.9% |
| 2015 | -0.90x | AU$-3.15 Million | AU$3.52 Million | ▼ -49.3% |
| 2014 | -0.60x | AU$-2.61 Million | AU$4.36 Million | ▼ -50.7% |
| 2013 | -0.40x | AU$-1.61 Million | AU$4.04 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.